Targeting the Fas/Fas ligand pathway in cancer

被引:64
作者
O'Brien, DI [1 ]
Nally, K [1 ]
Kelly, RG [1 ]
O'Connor, TM [1 ]
Shanahan, F [1 ]
O'Connell, J [1 ]
机构
[1] Univ Hosp Cork, NUIC, Dept Med, Cork, Ireland
关键词
apoprosis; chemotherapy; drug resistance; Fas/CD95; Fas ligand/CD95L; inflammation; interferon (IFN)-gamma;
D O I
10.1517/14728222.9.5.1031
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (Fast). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.
引用
收藏
页码:1031 / 1044
页数:14
相关论文
共 134 条
  • [91] Okada K, 2000, CLIN CANCER RES, V6, P3560
  • [92] Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression
    Ossina, NK
    Cannas, A
    Powers, VC
    Fitzpatrick, PA
    Knight, JD
    Gilbert, JR
    Shekhtman, EM
    Tomei, LD
    Umansky, SR
    Kiefer, MC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (26) : 16351 - 16357
  • [93] Owen-Schaub L, 2000, INT J ONCOL, V17, P5
  • [94] Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages
    Park, DR
    Thomsen, AR
    Frevert, CW
    Pham, U
    Skerrett, SJ
    Kiener, PA
    Liles, WC
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (12) : 6209 - 6216
  • [95] A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice
    Peng, SL
    Robert, ME
    Hayday, AC
    Craft, J
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (03) : 1149 - 1154
  • [96] Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma
    Petak, I
    Danam, RP
    Tillman, DM
    Vernes, R
    Howell, SR
    Berczi, L
    Kopper, L
    Brent, TP
    Houghton, JA
    [J]. CELL DEATH AND DIFFERENTIATION, 2003, 10 (02) : 211 - 217
  • [97] Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
    Pitti, RM
    Marsters, SA
    Lawrence, DA
    Roy, M
    Kischkel, FC
    Dowd, P
    Huang, A
    Donahue, CJ
    Sherwood, SW
    Baldwin, DT
    Godowski, PJ
    Wood, WI
    Gurney, AL
    Hillan, KJ
    Cohen, RL
    Goddard, AD
    Botstein, D
    Ashkenazi, A
    [J]. NATURE, 1998, 396 (6712) : 699 - 703
  • [98] LOCAL FAS/APO-1 (CD95) LIGAND-MEDIATED TUMOR-CELL KILLING IN-VIVO
    RENSINGEHL, A
    FREI, K
    FLURY, R
    MATIBA, B
    MARIANI, SM
    WELLER, M
    AEBISCHER, P
    KRAMMER, PH
    FONTANA, A
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (08) : 2253 - 2258
  • [99] Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1β, and the production of interferon γ in the absence of IL-12 during DC-T cell cognate interaction:: A new role for Fas ligand in inflammatory responses
    Rescigno, M
    Piguet, V
    Valzasina, B
    Lens, S
    Zubler, R
    French, L
    Kindler, V
    Tschopp, J
    Ricciardi-Castagnoli, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (11) : 1661 - 1668
  • [100] A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection
    Rodriguez, I
    Matsuura, K
    Khatib, K
    Reed, JC
    Nagata, S
    Vassalli, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) : 1031 - 1036